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Abstract
Chronic pancreatitis is defined as a continuous or recurrent inflammatory disease of the pancreas characterized by
progressive and irreversible morphological changes. It typically causes pain and permanent impairment of
pancreatic function. In chronic pancreatitis areas of focal necrosis are followed by perilobular and intralobular
fibrosis of the parenchyma, by stone formation in the pancreatic duct, calcifications in the parenchyma as well as
the formation of pseudocysts. Late in the course of the disease a progressive loss of endocrine and exocrine
function occurs. Despite advances in understanding the pathogenesis no causal treatment for chronic pancreatitis
is presently available. Thus, there is a need for well characterized animal models for further investigations that
allow translation to the human situation. This review summarizes existing experimental models and distinguishes
them according to the type of pathological stimulus used for induction of pancreatitis. There is a special focus on
pancreatic duct ligation, repetitive overstimulation with caerulein and chronic alcohol feeding. Secondly, attention
is drawn to genetic models that have recently been generated and which mimic features of chronic pancreatitis in
man. Each technique will be supplemented with data on the pathophysiological background of the model and
their limitations will be discussed.
Introduction
Chronic pancreatitis is defined as a continuous or
recurrent inflammatory disease of the pancreas charac-
terized by progressive and irreversible morphological
changes. It typically causes pain and permanent impair-
ment of pancreatic function. In chronic pancreatitis,
areas of focal necrosis are typically followed by perilob-
ular and intralobular fibrosis of the parenchyma, by
stone formation in the pancreatic duct and by the
development of pseudocysts. Late in the course of the
disease, a progressive loss of endocrine and exocrine
function occurs [1-3].
With an incidence of 8.2, a prevalence of 27.4 per 100
000 population and a frequency of presence in 0.04% to
5% of all autopsies performed, chronic pancreatitis
represents a common disorder of the gastrointestinal
tract [4-6]. The etiology of this disease is complex and
so far a variety of environmental factors including alco-
hol use, smoking and exposure to other toxic agents as
well as endogenous factors such as genetic variations
have been described. Chronic pancreatic and biliary
tract obstruction or congenital malformations also con-
tribute to development of chronic pancreatitis. Despite
advances in the diagnosis of chronic pancreatitis, avail-
able treatments are still unsatisfactory because therapeu-
tic concepts are mostly restricted to relieving symptoms
rather than changing the natural history [6,7].
Pathophysiology
The pathogenesis of chronic pancreatitis is still poorly
understood. Alcohol use is the leading risk factor and
the most common etiology [8]. At present there are four
competing hypotheses concerning the pathogenesis of
chronic pancreatitis that are largely historic. According
to Bordalo et al., ethanol induces a fatty degeneration of
acinar tissue similar to that seen in hepatocytes during
alcoholic liver disease. Ethanol has either a direct or an
indirect toxic effect, mediated by the ethanol metabolite
acetaldehyde, on the integrity of pancreatic acinar cells
[8-10].
Braganza et al. proposed a toxic effect of oxygen-
derived free radicals on pancreatic acinar cells. Oxidative
stress caused by nicotine or ethanol could lead to the
peroxidation of the lipid bilayer of the cell membrane,
which consecutively disintegrates the membrane [11].
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protective antioxidant mechanisms, as shown for some
cytochrome P450 enzyme pathways in the liver. This
hypothesis initiated several clinical studies that tested
antioxidants for the treatment of chronic pancreatitis,
resulting in some promising observations [12-14]. A
large European multicenter study testing the effect of
antioxidant treatment in patients with idiopathic chronic
pancreatitis is presently recruiting (NCT00142233).
A third hypothesis by Sarles and Sahel proposed a
destruction of pancreatic acini due to ductal hyperten-
sion resulting from primary intraductal obstruction by
protein precipitates as the cause of pancreatitis. This
hypothesis asserts that chronic alcohol consumption
leads to a decrease in bicarbonate concentration and
fluid volume in pancreatic secretions and is therefore
associated with the precipitation of protein and calcium
crystals within the duct lumen, which ultimately causes
duct obstruction. To avoid stone formation, it would be
necessary for the acinar cells to produce a low molecu-
lar weight protein called lithostatin that would, in turn,
increase the fluidity of pancreatic juice and prevent pre-
cipitation of protein plaques and calcite crystals in cal-
cium-supersaturated pancreatic juice. The validity of
this hypothesis has been questioned because others have
failed to confirm a decreased concentration of lithosta-
tins in pancreatic juice from patients with chronic pan-
creatitis or could not demonstrate an inhibitory function
of lithostatins on calcium carbonate precipitation.
Nevertheless, the role of duct plugging in cystic fibrosis
is unquestioned [15,16]. Klöppel and Maillet revisited
the hypothesis of Comfort and colleagues arguing that
chronic pancreatitis is a consequence of recurrent epi-
sodes of acute pancreatitis [17]. Focal fat necrosis and
necrosis of the pancreatic parenchyma would lead to the
infiltration of lymphocytes, macrophages and fibroblasts.
Fibrosis would thus be assumed to be a consequence of
necrosis. This hypothesis would be in accordance with
premature intracellular zymogen activation in pancreatic
acini as an underlying cause of recurrent bouts of acute
pancreatitis, which subsequently lead to the develop-
ment of chronic pancreatitis. This pathomechanism is
also suspected to be the cause of hereditary pancreatitis,
which is associated with mutations in the cationic tryp-
sinogen gene [18]. Most of the clinical and experimental
evidence suggests that this latter hypothesis predicts the
pathophysiology of chronic pancreatitis most accurately.
Pathophysiology of the development of fibrosis
Pancreatic fibrosis is a constant histopathological feature
of chronic pancreatitis of all etiologies. Fibrosis is gener-
ally defined as the accumulation of excessive amounts of
extracellular matrix proteins in a tissue. It is now gener-
ally accepted that fibrosis is not a mere end product of
chronic injury, but an active dynamic process that may
be reversible in its early stages. An understanding of the
mechanisms responsible for the development of fibrosis
has the potential to lead to the development of thera-
peutic strategies to prevent or retard the fibrotic pro-
cess. Research into pancreatic fibrogenesis is a rapidly
expanding field, one that was given significant impetus
by the development of methods to isolate and culture
pancreatic stellate cells. On a cellular level and in line
with the hypothesis of Klöppel and Maillet, pancreatic
fibrosis is caused by activation of pancreatic stellate cells
(PSCs) that normally reside in the periacinar region of
the pancreas and rest in a quiescent state [19,20]. The
role of PSCs is also outlined in Figure 1. They express
two cytoskeletal marker proteins, desmin and glial fibril-
lary acidic protein (GFAP), and can therefore be easily
detected by immunostaining and differentiated from
fibroblasts. Even if PSCs are quiescent they fulfill an
important function for maintenance of synthesis and
degradation of the extracellular matrix (ECM) [21,22].
The most crucial step for fibrosis is activation of pan-
creatic stellate cells, which can occur via different
mechanisms (Figure 2). Ethanol and its metabolites, the
most important of which is acetaldehyde, cause oxida-
tive stress by reactive oxygen species (ROS) within the
gland and finally lead to activation of stellate cells. Sec-
ondly, various cytokines such as platelet-derived growth
factor (PDGF), transforming growth factor b (TGFb),
tumor necrosis factor a (TNFa)a sw e l la si n t e r l e u k i n s
(IL) 1, 6 and 10 can induce stellate cell activation
[22,23]. Third, lipopolysaccharides (LPSs) also activate
PSCs by interaction with Toll-like receptor 4 (TLR4)
expressed on their surface, indicating a role of endotox-
ins in the development of pancreatic fibrosis. Notably,
alcohol and LPS have a synergistic effect [24]. When
pancreatic stellate cells become activated they transform
into a myofibroblast-shaped cell type that is capable of
migrating easily and secreting increased amounts of
extracellular matrix proteins, in particular collagen type
I, laminin and fibronectin. Moreover, activated stellate
cells can also synthesize cytokines that stimulate PSCs
in an autocrine loop [25,26]. Positive staining for a
smooth muscle actin (a-SMA) indicates activated stel-
late cells. There is growing evidence that pancreatic stel-
late cells act as resident phagocytic cells and, upon
activation, they ingest neutrophils and antigens and thus
limit the extent of inflammation [27,28]. Progressive
fibrosis and destruction of the gland result in exocrine
and endocrine insufficiency. These can also be tested for
in animal models and are therefore briefly described.
Exocrine insufficiency is one sign of chronic pancreatitis,
and it normally occurs late in the course of the disease
because the pancreas has a great functional reserve. It is
defined as either global or partial reduction in the
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Page 2 of 16Figure 1 Role of pancreatic stellate cells (PSCs) in fibrosis. Activation of PSCs from a quiescent into a myofibroblast-like type and
proliferation occurs via several triggers and is perpetuated in an autocrine loop. Development of fibrosis is a complex process that requires
interaction of collagen and extracellular matrix production together with chemokine synthesis and phagocytosis.
Figure 2 Multiple activators for pancreatic stellate cells. Adjacent acinar cells as well as neutrophils, macrophages and platelets stimulate
pancreatic stellate cells (PSCs) in a paracrine manner involving growth factors, cytokines and reactive oxygen species (ROS). Bacterial endotoxin
lipopolysaccharide (LPS) acts on PSCs. Once activated there is autocrine stimulation perpetuated by transforming growth factor b (TGFb), tumor
necrosis factor a (TNFa) and interleukin 6 (IL-6). They further express extracellular matrix components such as collagens I, III and fibronectin, and
matrix metalloproteinases as well as their inhibitors.
Aghdassi et al. Fibrogenesis & Tissue Repair 2011, 4:26
http://www.fibrogenesis.com/content/4/1/26
Page 3 of 16secretion of lipase, amylase or proteases and bicarbonate
in the pancreatic juice. Clinical symptoms arise only
when lipase secretion is reduced to less than 10% of
normal [29]. In clinical practice measurement of exo-
crine function is performed by either direct or indirect
pancreatic function tests. Direct function tests are based
on measurement of pancreatic enzymes in the juice that
is collected via a duodenal tube, and is considered to be
the gold standard for assessing exocrine pancreatic func-
tion. However, indirect function tests can detect a
decreased amount of pancreatic enzymes in stool or
serum or, alternatively, evaluate the digestion of syn-
thetic substrates that are administered orally [30]. The
endocrine dysfunction in chronic pancreatitis, also
known as pancreatogenic diabetes, manifests with
abnormal glucose tolerance and evolves into overt dia-
betes mellitus. The underlying pathophysiology of dia-
betes in chronic pancreatitis is mainly based on the loss
of insulin secretion. However, there is some evidence
that insulin resistance might also contribute to diabetes.
Episodes of hypoglycemia can occur and may be lethal
due to a lack of countercontrol due to the parallel
absence of glucagon [31]. Diabetes mellitus is diagnosed
by abnormal glucose tolerance tests (OGTT), alterna-
tively a direct quantification of hypoinsulinemia can be
performed by measurements of serum levels of insulin
or c-peptide.
Animal models of pancreatic fibrosis
It should be noted that although a variety of animal
models for chronic pancreatitis exist, most of them have
been designed to activate pancreatic stellate cells as the
principal source of fibrosis. Animal models for studying
the development of organ fibrogenesis have been used
for many years, and originated in the 1960s when Lieber
and DeCarli performed a series of studies investigating
the effects of alcohol on the liver. Since then, different
animal models have been developed that focus on the
effects of alcohol or other pathophysiological stimuli on
the pancreas [32,33].
For a systematic presentation of the current animal
models, it is useful to group them according to the kind
of profibrotic stimulus used (Table 1). Several models
combine two or more stimuli to enhance the fibrogenic
effects, which makes classification a little more difficult.
For the purpose of a clearer presentation we will base
our review on the type of trigger employed. The most
popular models include ethanol feeding, repetitive caer-
ulein injections and surgical ligation of the pancreatic
duct. In addition there are an increasing number of
genetic models elucidating the role of one particular
gene in the pathogenesis of chronic pancreatitis.
Recently, immunological models have attracted more
interest, focusing on the role of leukocytes in fibrosis. In
the following sections animal models of pancreatic fibro-
sis will also be assessed according to the extent of fibro-
sis and organ destruction resulting in exocrine or
endocrine insufficiency, and their limitations outlined.
Pancreatic duct ligation
In 1856 Claude Bernard (1813 to 1878), a student of
Francois Magendie, not only reported that pancreatic
juice is capable of the emulsification and saponification
of lipids and was involved in the digestion of starch and
proteins, but also that injection of olive oil into the pan-
creatic duct of dogs leads to the development of acute
pancreatitis. His observations marked the beginning of a
century of intensive research into the mechanisms that
determine the onset of biliary pancreatitis. The first
investigator who systematically addressed the issue of
biliary pancreatitis was Eugene Lindsay Opie, who in
1901 published two autopsy reports from which he con-
cluded two mutually exclusive triggering mechanisms
for gallstone-induced pancreatitis [34,35]. He employed
a series of animal studies to try and support his hypoth-
eses. The first autopsy report found that an impacted
gallstone had occluded the orifice of the pancreatic duct
and the patient had died from acute pancreatitis [34].
When Opie simulated this finding by pancreatic duct
ligation in cats, he noted the development of pancreatic
tissue and fat necrosis and proposed pancreatic outflow
obstruction as the triggering event for acute pancreatitis.
Unfortunately, his first ‘impaired outflow hypothesis’
was rapidly forgotten after he published his second
hypothesis. In another patient who underwent a post
mortem examination he found a distinctly different
Table 1 Animal models for chronic pancreatitis according
to the type of stimulus
Model Stimulus
Duct ligation model Pancreatic duct ligation
Incomplete duct ligation
Occlusion with tissue glue, acrylate, glass
particles
Repetitive acute
pancreatitis
Serial caerulein injections
Serial L-arginine injections
Alcohol feeding Lieber-DeCarli formula
Genetic models Wistar Bonn/Kobori (WBN/Kob) rats
R122H transgenic mice
SPINK3-deficient (SPINK3(-/-)) mice
CFTR-deficient (cftr
m1UNC) mice and CFTR(-/-)
pigs
Kif3a-deficient mice
PERK-deficient (PERK(-/-)) mice
Interleukin 1b transgenic mice (elastase sshIL-
1b mice)
CFTR = cystic fibrosis transmembrane conductance regulator; PERK = protein
kinase R-like endoplasmic reticulum kinase.
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physiological relevance. The impacted stone at the
papilla of Vater had created a communication between
the common bile duct and the main pancreatic duct,
allowing the patient’s bile to enter the pancreatic duct.
K n o w i n go ft h ee x p e r i m e n t so fC l a u d eB e r n a r d ,O p i e
proposed the presence of infected bile in the pancreatic
duct as the triggering mechanism of pancreatitis (com-
mon channel hypothesis). Despite experimental and
clinical evidence that the ‘common channel hypothesis’
did not explain the pathophysiology of gallstone-induced
pancreatitis, it remained popular for more than 75 years.
The reasons were (a) the great simplicity with which
numerous investigators since Claude Bernard have
induced pancreatitis by injecting bile (or any other
detergent) into the pancreatic duct, and (b) the bile-
stained appearance of necrotic pancreatic tissue that any
surgeon who has operated on patients late in the course
of necrotizing pancreatitis is aware of. We, and others,
have tested Opie’s common channel hypothesis in the
past, employing the opossum model of acute necrotizing
pancreatitis. This model appears ideally suited to test
whether bile reflux into the pancreatic duct or blockage
of pancreatic secretion triggers pancreatitis [36,37]
because the opossum not only possesses a gallbladder, a
common bile duct and a single pancreatic duct, but also
a long communication between the two. If this common
channel is ligated at the papilla of Vater it creates a
communication between the pancreatic and bile ducts
through which bile could potentially flow [36]. Our
experiments showed consistently that neither a common
channel, nor reflux of bile into the pancreas is required
or likely to be involved in triggering acute necrotizing
pancreatitis [37,38].
The most accurate description of the pathophysiology
of gallstone pancreatitis is found in Opie’so r i g i n a l
report, in which he proposes ‘pancreatic outflow
obstruction’ as the most critical event for disease onset.
It is therefore probable that pancreatic duct obstruction
might also lead to chronic inflammation once the organ
is affected by acute injury. However, models for chronic
pancreatitis based on duct obstruction are not common
and there is only a minority of studies examining the
morphological and biochemical changes of the pancreas
after duct ligation [39-42]. One of the earliest of these
studies was conducted by Churg et al. in 1971 in dogs
[43]. After ligation of the common bile duct close to the
duodenum pancreatic tissue was explanted after 1 week
and examined for altered morphology. Architectural
changes were distinctive for chronic pancreatitis: pan-
creata exhibited atrophy of the acinar cells and were
characterized by loss of zymogen granules and fragmen-
tation of the rough endoplasmic reticulum (RER). Infil-
tration of fibroblasts, macrophages and leucocytes was
observed in the interstitial space preceding collagen
deposition. Luminal widening of the pancreatic ducts
was also observed and appeared to be increasing over
time after the ligation procedure, partly accompanied
with intraductal deposition of cell debris. Apparently the
development of pancreatic fibrosis varies among species,
as dogs developed later and milder parenchymal changes
compared to rats, although the ligation procedures were
quite similar. Similar results were observed by Watanabe
et al., who monitored fibrogenesis for up to 16 weeks
after duct ligation [44]. When performing studies in
mice the unique anatomy hampers the results: the
mouse pancreas consists of three lobes, a gastric, splenic
and a duodenal lobe, which drain their juice via indivi-
dual ducts. In about 70% of cases the splenic duct joins
the gastric duct, which finally opens into the common
bile duct. There are, unfortunately, variations of this
drainage because the anatomy of the mouse pancreas is
more complex. Usually the investigator separates the
splenic lobe from the rest of the pancreas, consisting of
the remaining gastric and duodenal lobe. One of the
advantages of this technique is to demonstrate that
changes in one distinct part of the organ are indeed
caused by mechanical obstruction of the pancreatic duct
whereas the rest of the organ remains unaffected and
can be used as a control. Secondly the animal does not
suffer from a complete loss of organ function. However,
this technique is technically challenging as the diameter
of the pancreatic duct is only 150 μm and experienced
surgical hands are needed to minimize trauma. The pan-
creatic duct ligation model allows investigation of later
effects in the course of chronic pancreatitis. One of the
most remarkable observations is the gradual replace-
ment of parenchymal and even fibrotic tissue by fatty
tissue after 2 weeks. This phenomenon fits clinical
observations in humans and findings at autopsy where
atrophy of the exocrine organ is paralleled by fatty tissue
replacement [45]. Interestingly, the islets of Langerhans
are preserved. In patients suffering from chronic pan-
creatitis exocrine function is maintained for a long time
even in advanced stages of the disease because the func-
tional reserve of the exocrine pancreas is very high and
symptoms of exocrine insufficiency only arise when
more than 90% of the parenchyma is lost [30,46]. Wata-
nabe et al. observed similar results in mice when out-
flow of about 60% of pancreatic juice was blocked by
ligation, but the mice maintained their weight.
The time point and the extent of impairment or even
loss of endocrine and exocrine function after duct liga-
tion differ greatly between the studies [47-51]. Glucose
intolerance with a concomitant decrease in insulin levels
was seen between 28 days and up to 6 to 12 months
and there can be a temporary increase of insulin levels
shortly after the ligation, which is considered to be a
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predominantly assessed directly by secretin stimulation
tests and measurement of bicarbonate and amylase out-
flow. The limiting factor for comparison of these studies
lies in the fact that investigators often combine pancrea-
tic duct ligation with other profibrotic procedures such
as ethanol administration, or they only perform an
incomplete ligation procedure, as described below. As
pancreatic stellate cells are considered to be responsible
for the generation of fibrosis, they are expected to
become activated upon the proinflammatory stimulus of
ligation. a-SMA expression, as an indicator for active
pancreatic stellate cells, was detected 7 days after liga-
tion and increased up to the tenth day [52]. Activation
of stellate cells is multifactorial and one of the triggers
seems to be pancreatic duct obstruction and concomi-
tant elevation of intraductal pressure [51,52].
A modification of the pancreatic duct ligation proce-
dure is incomplete duct obstruction, where the lumen is
only reduced by being partially blocked. Technically, a
tube (for example, a polyethylene tube) is inserted,
resulting in partial obstruction. Critics of the pancreatic
duct technique claim that a complete obstruction mainly
results in atrophy of the organ and does not necessarily
lead to the typical morphology of chronic pancreatitis.
In contrast, incomplete obstruction would produce
milder but more typical alterations of the tissue archi-
tecture [47]. In an alternative to ligation, the pancreatic
duct can be occluded by tissue glues such as acrylate or
prolamine or by glass particles, resulting in similar
changes to that described above [53,54].
Caerulein-induced pancreatitis
It is generally believed that the morphological changes
that characterize acute pancreatitis result from digestion
of the gland by enzymes that are normally synthesized
and secreted by pancreatic acinar cells [36,55,56]. Evi-
dence that support this notion include the observations
that (a) the morphological changes of severe pancreatitis
resemble those that are typical of digestive necrosis [57];
(b) pancreatic acinar cells synthesize digestive enzymes,
which when activated, lead to digestive necrosis of the
gland [58]; and (c) activated digestive enzymes have
been detected within the gland during severe pancreati-
tis [59]. Most of the potentially harmful digestive pro-
teases of acinar cells are normally synthesized and
secreted as inactive zymogens and are activated only in
the duodenum by brushborder enzymes [60]. As early as
in 1895 Mouret et al. reported that excessive cholinergic
stimulation is associated with the development of pan-
creatic injury determined by acinar cell vacuolization
and necrosis [61]. Mouret et al. suggested that the acti-
vation of trypsin might be actively involved in the devel-
opment of acute pancreatitis. This hypothesis was in
accordance with the observations of Hans Chiari, who
proposed autodigestion to be the pathomechanism
underlying acute pancreatitis in 1896 [55]. Subsequently,
experimental animal models employing cholinergic ago-
nists such as carbamylcholine and charbachol, cholecys-
t o k i n i n( C C K )a n di t sa n a l o g s ,a sw e l la ss c o r p i o n
venom were shown to induce pancreatic injury in a
manner both time and dose dependent [62-66]. In
rodents CCK plays a major role in regulating exocrine
pancreatic secretion after stimulation by food ingestion.
However, human pancreatic acinar cells may not
respond directly to CCK stimulation but are mostly
regulated by cholinergic pathways that involve neuro-
genic CCK stimulation [67]. In 1977 Lampel and Kern
characterized the clinical and biochemical patterns of
acute interstitial pancreatitis in rats after administration
of excessive doses of pancreatic secretagogue [68]. The
most prominent morphological characteristic is the
development of excessive edema as early as 1 h after the
onset of the disease [69]. Since that time the model of
pancreatitis induced by caerulein (a CCK analog derived
f r o mt h eA u s t r a l i a nt r e ef r o gLitoria caerulea)i n
rodents is widely used and one of the best characterized
experimental varieties.
The primary physiological effect of CCK and its ana-
logs on the pancreas is to stimulate protein-rich secre-
tion; it has a lesser effect on fluid and electrolyte
secretion. Doses of CCK that lead to continued maximal
stimulation of enzyme secretion are associated with
increased rates of both protein synthesis and the move-
ment of newly synthesized proteins through the secre-
tory pathway. The increase in protein synthesis is
outpaced by the rate of protein secretion. Thus, follow-
ing stimulation with maximal secretory doses of caeru-
lein, the enzyme stores of the exocrine pancreas may be
reduced by as much as 75% within several hours.
Increasing the concentration of CCK by an order of
magnitude over the levels that produce maximal secre-
tion is known as supraoptimal stimulation, supramaxi-
mal stimulation or hyperstimulation [69]. Compared to
maximal stimulation, supramaximal stimulation gener-
ates a distinct pancreatic response that includes dimin-
ished secretion, accumulation of secretory proteins
within the pancreas and pancreatic injury. The route of
administration for caerulein that induces acute pancrea-
titis differs in various rodents, as does the severity of the
disease [70-73]. While in rats caerulein can be continu-
o u s l yi n f u s e di n t r a v e n o u s l ye i t h e rv i aap o l y e t h y l e n e
catheter placed into the external jugular vein or into the
tail vein, in mice caerulein is generally injected repeat-
edly into the peritoneal cavity [74]. The caerulein con-
centration that results in pancreatic edema, increased
serum levels of pancreatic enzymes, inflammation and
necrosis ranges between 5 to 10 μg/kg/h in rats and
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10-fold to 20-fold. Maximal pancreatic injury occurs
after 12 h of continuous infusion but changes can be
monitored already 15 minutes after the start of the caer-
ulein infusion and resolve spontaneously after 24 to 48
h. One of the earliest consequences of hyperstimulation
is the formation of pancreatic edema. This increase in
pancreatic fluid, which occurs within the first hour of
caerulein hyperstimulation, is probably the result of sev-
eral factors: increased vascular permeability, increased
hydrostatic pressure from the constriction of small ves-
sels and increased tissue oncotic pressure from the
interstitial release of pancreatic enzymes and hydrolytic
products. Under the conditions of supramaximal caeru-
lein stimulation, secretion of zymogens into the pan-
creatic duct is virtually abolished and premature
zymogen activation can be observed after a sustained
intracellular calcium rise and a breakdown of the actin
cytoskeleton. These events lead to a systemic inflamma-
tory response syndrome, which includes extrapancreatic
damage such as pancreatitis related lung injury.
One of the most frequently used methods to induce
chronic fibrotic changes in the pancreas is to perform
self-limited acinar cell injury by repeated pathological
stimuli of the gland. The kind of stimulating agent and
the intervals are variable. This method mimics the clini-
cal observation that repeated episodes of acute pancrea-
titis, irrespective of its origin, lead to increasing damage
of the organ that eventually results in atrophy and fibro-
sis [75]. At the beginning of the recovery period the
pancreas produces components of extracellular matrix
that temporarily exceed the degradation of the extracel-
lular proteins [20]. Secondly, profibrotic cytokines are
released leading to an environment that favors fibrosis.
One of the most potent fibrogenic modulators is
TGFb1, which is overexpressed in pancreatic acinar and
stromal cells after caerulein-induced pancreatitis [76,77].
In this phase the organ is extremely vulnerable to
repeated episodes of acute pancreatitis and will not be
able to degrade the ECM components, which finally
promotes fibrosis after a number of repeated injuries
[78]. Neuschwander-Tetri et al. performed injections
twice a week for 10 weeks in mice and could observe
prominent fibrotic changes of the pancreas. Due to the
dysbalance between accumulation and degradation of
extracellular matrix in this experimental set-up, an
increased collagen production started around the second
week and mainly consisted of collagen type I deposited
in the periacinar region. In regions with severe fibrosis,
acinar cells displayed features of ductal cells with loss of
zymogen granules and a more centrally located nucleus.
Since they also surround the lumen of tubular structures
they were termed ‘tubular complexes’ that are typically
found in chronic pancreatitis [79,80].
Repetitive caerulein injections alone only cause minor
effects on endocrine cells as shown in studies performed
in rats. Since metabolic impairment normally occurs late
in the course of the disease animals were challenged by
a second stimulus to accelerate development of chronic
pancreatitis. In one model water immersion stress was
used, which provokes repeated tissue ischemia and
reperfusion. Here, rats showed a diabetic pattern with
elevated blood sugar and reduced insulin levels [81,82].
These findings also led to the assumption that caerulein
injections alone were not sufficient to provoke endo-
crine dysfunction and that toxins have to be used to
increase the severity of chronic pancreatitis. Data on
exocrine insufficiency in an animal model of repetitive
caerulein injections are rare. According to the observa-
tions of Ohashi et al. deficiency in exocrine function
can occur after 6 weeks by significant decrease of pan-
creatic protein content that was used as an indicator for
exocrine function [83]. Wistar Bonn/Kobori (WBN/Kob)
rats with chronic pancreatitis that sequentially under-
went intravenous applications of caerulein showed more
severely impaired dysfunction assessed by cholecystoki-
nin-stimulated flow rate, bicarbonate output, and pro-
tein output compared to untreated rats [84]. However it
has to be considered that WBN/Kob rats themselves
already develop chronic pancreatitis even if there is no
additional trigger for pancreatitis. In summary, exocrine
pancreatic insufficiency can be achieved in a caerulein
model, but for endocrine insufficiency more than one
trigger or predisposing factor for pancreatitis is required.
There are many variations regarding the amount and
frequency of caerulein injections and extension of fibro-
sis is highly variable [83,85,86]. Studies using lower caer-
ulein concentrations or fewer injections such as only
once a week or even every third week have shown that
architectural alterations of the pancreas develop later
and occur as late as 1 year after onset of injections. It is
likely that there is a dose dependency for caerulein, a
dependency on the injection intervals and the extension
of pancreatic damage. Using higher frequencies of caer-
ulein applications will lead to rapid formation of pan-
creatic fibrosis.
The l-arginine model
The essential amino acid L-arginine has been shown to
cause acute pancreatitis in murine and rat models
[87-89]. With the aim to establish a non-invasive animal
model burdened with a significant mortality, in 1984
Mizunuma et al. developed a new type of experimental
pancreatitis by intraperitoneal administration of high
concentrations of L-arginine in rats [90]. In subsequent
s t u d i e si tw a ss h o w nt h a tL -arginine leads, in a dose
dependent manner, to acinar cell necrosis levels of up to
100%. At 24 h after the first intraperitoneal injection the
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tions reveal partial distension of the endoplasmic reticu-
lum. At 48 h after the onset of pancreatitis dissociation
and necrosis of acinar cells was noted. Subsequently,
necrotic cells are replaced by interstitial tissue composed
of leukocytes and fibroblasts [91,92]. The mechanism by
which L-arginine causes pancreatitis is not fully under-
stood. Furthermore, the crucial question of whether
excessive concentrations applied intraperitoneally cause
premature intracellular zymogen activation is not
answered. Several reports suggest that oxygen free radi-
cals, nitric oxide and inflammatory mediators might play
a key role. Long-term administration of L-arginine for
30 days induces pancreatic atrophy, with exocrine pan-
creatic insufficiency resembling the clinical picture of
chronic pancreatitis [93]. Histological changes appear
slightly later than in caerulein-induced pancreatitis (40
days in arginine pancreatitis compared to 35 days in
caerulein-treated animals) and morphological changes
mainly consist of collagen IV depositions around acini,
vessels and ducts. After 2 months normal pancreatic
parenchyma was replaced by fatty tissue and ducts
showed caliber dilations [94]. There are even studies
indicating that fibrotic changes can appear as early as 1
week after onset [92].
Combination of repetitive caerulein injections with toxins
and other agents
There are several reports showing that the combination
of serial caerulein injections together with other proin-
flammatory agents enhances pancreatic fibrogenesis.
Table 2
Toxic agents frequently used in addition to serial caer-
ulein injections
Lipopolysaccharides (LPS)
Cyclosporin A (CsA)
Dibutyltin dichloride (DBTC)
Ethanol
Secondly, intraperitoneal caerulein injections can also
be administered in genetically transformed mice to
enhance the effects. Due to its ease of use the repetitive
caerulein model has evolved to be a popular method for
generation of pancreatic fibrosis. LPS is the major com-
ponent of the outer membrane of Gram-negative bac-
teria, contributing greatly to the structural integrity of
the bacteria, and protecting the membrane from chemi-
cal attack. LPS also increases the negative charge of the
cell membrane and helps stabilize the overall membrane
structure. It is of crucial importance to Gram-negative
bacteria, whose death results if it is mutated or
removed. LPS is an endotoxin, which induces a strong
immune response in animals (Figure 3). When attached
to LPS binding protein (LBP), an acute phase protein,
this complex binds to CD14, which further activates
TLR4. TLR4 mediates an intracellular signaling cascade
involving the adapter protein myeloid differentiation pri-
mary response gene 88 (MyD88) and serine/threonine
kinases leading finally to a dissociation of the IB/
nuclear factor (NF)B complex [95-99]. This dissolution
is a prerequisite for activation of NFkB, which enters
the nucleus and stimulates synthesis of proinflammatory
cytokines in monocytes and macrophages [95,100].
Recently it was shown that, as well as in immune cells,
pancreatic stellate cells also express CD14 and TLR4,
suggesting a direct effect of LPS on PSCs [24]. LPS
aggravates acute pancreatitis when applied intraperitone-
ally or intravenously [101]. LPS also accelerates the
development of chronic pancreatitis as shown by Ohashi
et al. In this study the effect of caerulein alone and the
combination of LPS with caerulein in mice was moni-
tored [83].
Table 2
Toxic agents frequently used in addition to serial caer-
ulein injections
Lipopolysaccharides (LPS)
Cyclosporin A (CsA)
Dibutyltin dichloride (DBTC)
Ethanol
Figure 3 Lipopolysaccharide (LPS)-dependent and nuclear
factor (NF)B-mediated activation of proinflammatory
cytokines. LPS binds to LPS-binding protein (LBP) and forms a
complex with the surface protein CD14 that further interacts with
MD-2 associated Toll-like receptor 4 (TLR4). Myeloid differentiation
primary response gene 88 (MyD88) is recruited to TLR4 by its Toll-
interleukin 1 receptor (IL1R) (TIR) domain and further activates
serine/threonine kinase interleukin 1 receptor-associated kinase
(IRAK) by its death domain (DD). After recruitment of tumor necrosis
factor receptor associated factor 6 (TRAF-6), another adapter protein,
mitogen-activated protein kinase kinase kinase (MAPKKK)
transforming growth factor b activated kinase (TAK1) is activated
that phosphorylates the inhibitor of B kinase (IKK) complex.
Activated IKK removes inhibitory IB from the IB-NFB complex so
that NFB can enter the nucleus and where it stimulates the
expression of proinflammatory chemokines. In a second pathway,
which is not listed here, TAK1 is able to activate MAP kinases p38
and c-Jun N-terminal kinase (JNK).
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LPS to caerulein increases destruction of pancreatic
acini. Mice were treated with caerulein (50 μg/kg body
weight) or both caerulein and LPS (3,125 mg/animal)
twice a week for 10 weeks. Thereafter mice were killed
and pancreata were subjected for histological analysis.
Both groups showed acinar cell atrophy, invasion of leu-
cocytes and formation of tubular complexes. Pancreata
of mice that were treated with caerulein and LPS had
more severe signs of chronic pancreatitis (Figure 4A).
Masson-Goldner trichrome stains visualized the exten-
sion of fibrosis that was enhanced after addition of LPS
(Figure 4B). Control animals that were treated with PBS
alone did not show any signs of chronic pancreatitis.
Lipopolysaccharides are toxic and animals die from ana-
phylaxis after exposure to LPS. Therefore dose-response
experiments for determination of the right LPS dose are
needed [102]. Cyclosporin A (CsA) is a widely used
immunosuppressant used after organ transplantation
and one of its mode of action is to induce TGFb expres-
sion. Due to the effect of TGFb on pancreatic stellate
cells and its capability to inactivate collagenases CsA
shifts the balance to a profibrogenic state. Cyclosporin
A treatment alone temporarily raised TGFb blood levels
but pancreatic morphology was mostly conserved and
did not show characteristic signs of chronic pancreatitis.
In combination with caerulein injections prominent his-
tological damage with increased collagen deposition and
glandular atrophy was observed, which exceeded the
effects of caerulein alone. Moreover CsA is also able to
reduce pancreatic blood flow and thus potentiates the
damage to the gland [103]. In a model termed the
‘cyclosporin A model of alcoholic chronic pancreatitis’
by Gukovsky et al. addition of CsA to caerulein in rats
that were additionally fed with ethanol led to a decrease
of pancreatic parenchyma by approximately 86% and a
severe impairment of the functional reserve. In particu-
lar, ethanol feeding was responsible for extensive fibrosis
and impaired regeneration [104]. One of the limitations
of cyclosporin A treatment is that it accumulates in the
pancreas and can directly cause morphological and
functional changes to the organ such as cellular atrophy
Figure 4 Histological changes of pancreatic tissue architecture after repetitive caerulein and combined caerulein-lipopolysaccharide
(LPS) injections. (A) Hematoxylin and eosin staining indicates destruction of pancreatic acinar cells and development of tubular complexes, a
sign of chronic pancreatitis. (B) Masson-Goldner trichrome stain denotes fibrosis; connective tissue is stained green. Caerulein and LPS increase
pancreatic fibrosis compared to caerulein alone. Phosphate-buffered saline (PBS)-treated mice did not develop chronic pancreatitis and were
used as negative controls.
Aghdassi et al. Fibrogenesis & Tissue Repair 2011, 4:26
http://www.fibrogenesis.com/content/4/1/26
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concentration dependent and therefore CsA needs to be
titrated to avoid local toxic effects [105].
Induction of toxic damage to the pancreas can be
achieved by dibutyltin dichloride (DBTC), a compound
that belongs to the chemical class of organotins that are
industrially used for heat stabilization of polyvinylchlor-
ide plastics, as biocides in agriculture, and by ship-
builders as antifouling paint. The twofold effects of
DBTC on the pancreas are mediated by a biliary
obstructive component and secondly a direct toxic
effect. Organotins are rapidly excreted via the bile and
cause damage to the bile duct epithelium with subse-
quent necrosis and duct obstruction. Due to cholestasis,
biliary pancreatitis and pancreatic necrosis develop. The
second effect of DBTC is mediated by its direct toxic
effect on acinar cells, mediated via hematogenic trans-
port to the gland. Repeated intravenous applications of
DBTC at intervals of 3 weeks induce acute interstitial
pancreatitis in the first week and later interstitial and
periductular fibrosis which are detectable after 6 weeks
[106-108]. It has to be taken into account that this
model also induced severe damage to the liver including
bile duct hyperplasia, inflammatory cell invasion and
parenchymal necrosis. Dibutyltin dichloride has a half-
life of about 2 days, and there is a dose-dependent rela-
tion of DBTC and the toxic effects on the pancreas and
the liver. Due to its dependence on bile duct anatomy
this model is only applicable in rats.
Inhibitory factors for development of pancreatic fibrosis
In line with the pathophysiological concept put forward
by Joan Braganza, oxidative stress caused by ROS is
known to be proinflammatory and favors acute and
chronic pancreatitis by direct damage of cells as well as
by activation of inflammatory cells and pancreatic stel-
late cells [109]. Overexpression of thioredoxin (TRX-1),
which is an endogenous anti-inflammatory and antioxi-
dative protein attenuated pancreatic fibrosis in a model
of repeated caerulein injections in TRX-1 transgenic
mice. Monocyte chemotactic protein 1 (MCP-1), a very
potent attractant for inflammatory cells that further
synthesize profibrotic chemokines, was significantly
reduced in this model. Furthermore, exocrine function
was preserved [83]. TGFb is a pleiotropic cytokine con-
sisting of different isoforms with an anti-inflammatory
effect via suppression several proinflammatory cytokines
such as interferon g (IFNg), various interleukins, and T
and B cells as well as macrophages. However, TGFb can
also be profibrogenic as it activates stellate cells and
thus promotes fibrosis in different organs such as the
liver and the pancreas. Inhibition of the TGFb signaling
pathway ameliorated pancreatic fibrosis. A dominant-
negative mutant of the TGFb receptor or overexpression
of Smad7, an intracellular protein that negatively regu-
lates TGFb signaling results in significantly reduced
fibrosis in experimental pancreatitis models [110,111].
Repeated alcohol feeding
Alcohol use is one of the main causes of acute and
chronic pancreatitis in Western countries but there is
still much controversy about how chronic alcohol con-
sumption leads to chronic pancreatitis. About 70% of
chronic pancreatitis cases are associated with alcohol
abuse but less than 10% of chronic alcoholics develop
chronic pancreatitis [75,112].
Alcoholic-induced pancreatic damage is thought to be
caused by different effects of ethanol and its metabolites.
In the liver alcohol can be metabolized, whereas in the
pancreas the relevant enzymes necessary for metabolism
are not expressed [113,114]. Thus toxic compounds
exert different effects on the pancreas. ROS are bypro-
ducts of ethanol metabolism and have a direct toxic
effect on pancreatic acinar cells. Secondly, pancreatic
stellate cells as the major source of fibrosis are activated
by ROS [21]. In isolated acini of ethanol-fed animals
trypsin and chymotrypsin activation was markedly
increased upon cholecystokinin stimulation compared to
control animals [115].
Due to the high impact of ethanol on pancreatic dis-
eases alcohol was frequently used as a trigger for
chronic pancreatitis in animal models, and the first ani-
mal models for chronic pancreatitis ever developed were
based on alcohol feeding. One of the earliest studies
investigating the effects of ethanol administration on dif-
ferent organs was published by Lieber and DeCarli, who
repeatedly fed rats and baboons with ethanol as part of
their diet [116,117]. The animals developed fatty liver
disease, alcoholic hepatitis and later on cirrhosis. The
feeding regime, which was named the ‘Lieber-DeCarli
Formula’, was based on supplementation of ethanol to a
liquid diet and allows an increased total alcohol intake
compared to that possible with pure ethanol feeding
alone. It has been shown to be one of the most useful
methods to imitate the effects of alcohol on various
organs. In 1971 Sarles et al. observed histological
changes in the pancreas comparable to chronic pancrea-
titis in more than 50% of Wistar rats after chronic
intake of ethanol for 20 to 30 months [118]. The dura-
tion of ethanol feeding differs among studies, and
mostly varies between 4 weeks and 16 months although
longer observation times have been reported [112]. It is
well documented that ethanol leads to severe organ
damage in the liver but pancreatic morphology changes
are milder; rather than chronic pancreatitis only mild
functional insufficiency develops in most cases. These
observations correlate with the clinical finding that only
a minority of alcoholics ever develop chronic
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sumption. Ethanol supplementation to daily food for a
total of 6 months in rats resulted in exocrine impair-
ment but not in morphological changes characteristic
for chronic pancreatitis [112]. Even administration by
continuous intragastric infusion could not cause chronic
injury to the pancreas of rats. It is therefore still contro-
versial whether a satisfactory model for chronic pancrea-
titis induced by ethanol alone is feasible, and it is more
likely that ethanol has to be regarded as a cofactor for
the development of fibrosis in ‘preinjured’ animals.
Moreover, alcohol diet or infusions not only cause
damage in the pancreas but also to many other organs
such as the liver, kidneys and lungs, which has to be
taken into account when studying systemic effects
[32,118,119].
The combination of alcohol feeding with caerulein
injections exacerbates the course of pancreatitis and
increases pancreatic fibrosis and loss of parenchyma.
Additionally, calcifications indicating severe chronic
pancreatitis can be observed. Data on functional impair-
m e n ta r es p a r s eb u tt h e r ei se v i d e n c et h a td i g e s t i v e
enzyme synthesis is reduced after chronic ethanol feed-
ing [104,120-122]. All in all, the majority of studies indi-
cate that ethanol administration alone only causes few,
if any, changes that are typical for chronic pancreatitis,
which implies that alcohol mainly serves as a sensitizer
to chronic injury.
Hereditary animal models on chronic pancreatitis
Chronic pancreatitis is a complex inflammatory disease
and over the past decade there have been increasing
efforts focusing on genetic abnormalities that predispose
people to chronic pancreatitis. Genetic analyses can
identify pancreas-specific factors that are associated with
higher or lower susceptibility to acute or chronic pan-
creatitis. Activation of trypsinogen is one of the key
events in the early phase of pancreatitis and therefore
genetic abnormalities found in the trypsinogen gene and
in its inhibitors might be of particular importance. In
addition, much attention is focused on cystic fibrosis, a
hereditary disease of chloride ion channels (cystic fibro-
sis transmembrane conductance regulator (CFTR))
accompanied by pancreatic fibrosis together with func-
tional defects of the lungs and the small intestine. How-
ever, there are some other genetic models that might
help us to understand how chronic pancreatitis devel-
ops, and those will be outlined below.
WBN/Kob rats
Male WBN/Kob rats endogenously develop chronic pan-
creatitis-like lesions. This strain, originating from a Wis-
tar rat colony at the University of Basel, was generated
at the University of Bonn in 1961 by brother-sister
inbreeding and was primarily reported by Kobori et al.
to be susceptible to tumor induction in the glandular
stomach [123,124]. The first changes were described
after 3 months of age, starting with periductular fibrosis
leading to extensive parenchymal loss and fibrosis pro-
gressing rapidly with age. Exocrine and endocrine func-
tion was also impaired as demonstrated by reduced
excretion of N-benzoyl-L-tyrosyl-p-aminobenzoic acid
(NBT-PABA) in the urine and glycosuria [125]. Even-
tually WBN/Kob rats become diabetic at 60 to 90 weeks
of age. Thus WBN/Kob rats emerged as a useful animal
model for studying chronic pancreatitis because they
show both morphological and biochemical changes typi-
cal of this disease. So far the underlying mechanism is
incompletely understood, and several possibilities are
being discussed. Chronic pancreatitis only occurs in
male rats around the time when the animals become
sexually mature and androgen synthesis is increased.
Furthermore, estradiol treatment ameliorates diabetic
symptoms whereas ovariectomy causes pancreatic fibro-
sis in females. These findings suggest that sex hormones
are involved in the development of chronic pancreatitis.
Enhanced apoptosis of acinar cells was found in WBN/
Kob rats preceding the infiltration of inflammatory cells
and was reversible after glucocorticoid treatment, sug-
gesting that programmed cell death might be of impor-
tance for the loss of parenchymal cells. Mitochondrial
swelling after ischemia and stasis of pancreatic juice
were further reported to be responsible for early pan-
creatic changes [125,126]. Chromosomal mapping of
WBN/Kob rats showed a unique haplotype block in the
chromosomal region Pdwk1 (pancreatitis and diabetes
mellitus in WBN/Kob locus 1) on chromosome 7 after
identification of nucleotide polymorphisms of three can-
didate genes that were not found in other inbred rat
strains [127]. These genes (Rac2, Grap2 and Xpnpep3)
exert different functions. Rac2 encodes for a GTPase
that belongs to the RAS superfamily and is involved in
diverse cellular events including apoptosis and phagocy-
tosis. Grap2 is an adaptor protein involved in leukocyte
specific protein tyrosine kinase signaling, whereas
Xpnpep3 is a mitochondrial protein important for
proper ciliary function [128]. Clearly, genetic alterations
play a role in pancreatic fibrosis of this rat strain.
Transgenic expression of R122H trypsinogen
The premature trypsinogen activation within the pan-
creatic parenchyma is a crucial event for the initiation
of pancreatitis. Once activated, trypsin is able to activate
other digestive proenzymes in the pancreas. In 1996
Whitcomb et al. reported on arginine-histidine mutation
(R122H) in human cationic trypsinogen (PRSS1) that is
associated with an autosomal dominant, hereditary pan-
creatitis phenotype; a rare type of pancreatitis
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[129]. A transgenic mouse model carrying the missense
mutation R122H in murine trypsin 4 displayed pancrea-
tic fibrosis and acinar cell dedifferentiation with progres-
sing age. Another model using R122H mutated human
trypsinogen, which was expressed under control of a rat
elastase-2 promoter in the mouse pancreas, showed ele-
vated levels of lipase but no spontaneous development
of chronic pancreatitis. Both mouse models were more
susceptible to caerulein-induced pancreatitis developing
more severe pancreatitis underscoring the importance
PRSS1 mutations as a pathogenic mediator [130,131].
Interestingly, in a recently published model by Gaiser
and coworkers intra-acinar expression of active trypsin
in vivo was sufficient to induce acinar death and local
and systemic inflammation. Of note, intra-acinar active
trypsin led to acinar cell death by both necrosis and
apoptosis in vivo. Remarkably, sustained intra-acinar
trypsin activity resulting from repeated tamoxifen
administration every fifth day over 40 days led to mas-
sive acinar cell loss caused by ongoing cell death and
significant fatty replacement was observed. However,
there was no evidence of chronic inflammation or of
fibrosis; both hallmarks of chronic pancreatitis [132].
Mutations in other genes such as anionic trypsinogen
( P R S S 2 ) ,t h es e r i n ep r o t e a s ei n h i b i t o rK a z a lt y p e1
(SPINK1), CFTR, chymotrypsinogen C (CTRC) and cal-
cium-sensing receptor (CASR) are also associated with
an increased risk for pancreatitis [133,134]. A knockout
model of murine SPINK3, which is a homologue of
human SPINK1, is lethal within 2 weeks after birth. At
around 16.5 days after coitus acinar cells showed autop-
hagic degeneration with no signs of parenchymal regen-
eration. Enhanced trypsin activity was detected in
isolated acini [135,136]. Targeted overexpression of pan-
creatic secretory trypsin inhibitor I increased endogen-
ous trypsin inhibitor capacity by 190% in transgenic
compared to wild-type mice whereas trypsinogen activa-
tion remained constant. Severity of pancreatitis was
decreased in these transgenic mice [137].
Cystic fibrosis
Cystic fibrosis (CF) is a common autosomal recessive
disease with a carrier rate of about 5% in Caucasians. In
1989 the underlying gene was found, coding for a chlor-
ide channel that was named CFTR. Subsequently, more
than 1,000 gene mutations associated with cystic fibrosis
have been reported. The defective chloride channel
causes abnormal chloride transport through epithelial
cells leading to deficient fluid secretion and thickening
of secretions not only in the pancreas but also in the
respiratory airways, kidneys and intestine [138]. Pancrea-
tic excretory function is diminished in up to 90% of
patients with CF, and shows wide variations ranging
from complete loss of pancreatic function up to an
almost normal phenotype [134,139].
Mice homozygous for the disrupted CFTR gene
(cftrm1UNC) display many features of cystic fibrosis
patients such as meconium ileus, alterations of mucous
and serous glands and obstruction of glandular ducts by
inspissated material. Death occurs after around 40 days
of age by intestinal obstruction and ileus [140]. The exo-
crine pancreas of the CFTR knockout mouse is morpho-
logically altered with fewer zymogen granules and partly
dilated ducts filled with amylase-positive aggregates and
lined by high amounts of sulfated glycoproteins. The
duodenal pH of the CF mice was shifted to more acidic
condition, explained by decreased bicarbonate produc-
tion. Mild exocrine insufficiency was observed in CFTR
(-/-) mice that had less pancreatic enzyme secretion and
lower protein and mRNA levels of digestive enzymes.
Mice developed more severe acute pancreatitis after
caerulein hyperstimulation, which was explained by a
decrease of apoptosis and a higher baseline proinflam-
matory state indicated by constitutively higher expres-
sion of inflammatory cytokines [141,142]. In order to
establish a model that is closer to humans regarding
lifespan, genetics and physiology Rogers et al. recently
developed a porcine model with a CFTR defect [143].
Morphological changes were more distinct than those
described above and were similar to the findings in new-
born patients with cystic fibrosis. The limiting factor of
this model is, besides the more costly handling of ani-
mals, that all piglets develop meconium ileus with a
high risk of perforation and peritonitis. Therefore they
require surgery to resolve intestinal obstruction. The
overall survival of animals is less due to perioperative
and postoperative complications along with a failure to
thrive.
Other genetic models
Defects in cilia formation are associated with several
genetic diseases including polycystic kidney disease and
primary ciliary dyskinesia, also known as Kartagener
syndrome, that affects the cilia of the respiratory tract.
Absence of cilia in pancreatic epithelial cells produces
lesions that resemble chronic pancreatitis tissue. By con-
ditional inactivation of the Kif3a gene, encoding a subu-
nit of the kinesin-2 complex that is essential for cilia
formation fibrosis, lipomatosis and cyst formation was
observed in pancreatic tissue [144,145]. Disruption of
proper protein folding in the endoplasmic reticulum
(ER) results in accumulation of misfolded proteins and
finally ends up with altered gene expression and ER
stress. Protein kinase R-like endoplasmic reticulum
kinase (PERK), a transmembrane molecule of the endo-
plasmic reticulum, attenuates translation in response to
ER stress and absence of PERK renders cells to be more
Aghdassi et al. Fibrogenesis & Tissue Repair 2011, 4:26
http://www.fibrogenesis.com/content/4/1/26
Page 12 of 16susceptible to agents causing ER stress and protein mis-
folding [146]. PERK(-/-) mice rapidly experience a
decline of endocrine and exocrine pancreatic function,
observed between 4 and 8 weeks of age, which could be
attributed to increased apoptosis of insulin-producing
and acinar cells. Recently the importance of cytokines
was pointed out in a transgenic mouse model overex-
pressing human IL-1b in the pancreas. This cytokine
has been shown to be involved in acute pancreatitis and
pathogenesis of multisystem organ failure. Elastase
sshIL-1b mice consistently developed severe chronic
pancreatitis similar to human disease [147,148]. In this
model propagation of more proinflammatory cytokines
and recruitment of leucocytes triggered by IL-1b are
considered to be the underlying causes for fibrosis.
Another mechanism is a direct activation of stellate cells
and T lymphocytes that exert a cytotoxic effect on pan-
creatic cells [149]. The authors pointed out that the
severity of chronic pancreatitis correlated with the
expression of IL-1b. Compared to mice that were trea-
ted by serial caerulein injections for 20 weeks sshIL-1b
m i c eo ft h es a m ea g eh a dm o r es e v e r es i g n so fc h r o n i c
inflammation. No significant differences regarding pan-
creatic exocrine and endocrine function were detected.
Taken together, these findings underline the importance
of immune activation for chronic inflammation; sec-
ondly, the model might be a tool for investigation of
carcinogenesis in chronic pancreatitis as older IL-1b
transgenic mice display acinar-ductal metaplasia.
Conclusions
The intention of this review was to describe the most
frequently used and best established models for chronic
pancreatitis in animals. Most are rodent models, since
mice and rats are easy to handle and there is a steadily
increasing number of genetic models obtained by gene
deletion or transgenic expression of genetic variants.
Choosing the right model is difficult and the scientific
rationale needs to be carefully considered. Secondly, not
all models of chronic pancreatitis parallel all classical
symptoms and the question addressed is of importance
when choosing a model. Repetitive caerulein injections
are amongst the most widely used models. Technically,
caerulein injections are relatively easy to perform and
they show a high reliability and reproducibility. Another
advantage is that other compounds mediating injury
such as lipopolysaccharides or cyclosporin A can be
easily added. Third, serial caerulein injections can be
performed in transgenic or knockout animals and will
allow future studies to answer how different predisposi-
tions exert additive effects or abrogate each other,
depending on the gene that is overexpressed or deleted.
Established protocols notwithstanding, the right dose
and the optimal injection interval have to be established
in individual laboratory tests before each set of
experiments.
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